General MedicationsNASALGeneric

NASONEX

MOMETASONE FUROATE

Standard Dose

0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview NASONEX is listed in Drugs@FDA under application 020762 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient MOMETASONE FUROATE Form and strength SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON LLC Submission history Latest submission status date: 2022-06-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview NASONEX is listed in Drugs@FDA under application 020762 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MOMETASONE FUROATE Form and strength SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON LLC Submission history Latest submission status date: 2022-06-28 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.